earnings
confidence high
sentiment positive
materiality 0.80
BioMarin Q2 revenue $712M (+20% YoY), GAAP EPS $0.55 (+90%), raises FY2024 guidance
BIOMARIN PHARMACEUTICAL INC
2024-Q2 EPS reported
$1.01
revenue$1,360,862,000
- VOXZOGO revenue $183.9M (+62% YoY); ~3,500 children on treatment across 44 countries.
- GAAP net income $107.2M (+91% YoY); Non-GAAP EPS $0.96 (+78% YoY) vs $0.54.
- FY2024 guidance raised: total revenue, Non-GAAP operating margin, Non-GAAP EPS all increased.
- ROCTAVIAN restructuring: focus on US, Germany, Italy; target $60M annual expenses by 2025; Q2 rev $7M.
- Discontinued BMN 293 (gene therapy for hypertrophic cardiomyopathy); BMN 351/349/333 on track.